[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-369266-105":59,"doc-detail-369266-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","validation-of-a-breast-cancer-assay-for-radiotherapy-omission-an-individual-participant-data-meta-analysis","Validation of a breast cancer assay for radiotherapy omission: an individual participant data meta-analysis","","Background: There are currently no molecular tests to identify individual breast cancers where radiotherapy (RT) offers no benefit. Profile for the Omission of Local Adjuvant Radiotherapy (POLAR) is a 16-gene molecular signature developed to identify low-risk cancers where RT will not further reduce recurrence rates. Methods: An individual participant data meta-analysis was performed in 623 node-negative, ER-positive, HER2-negative patients across 3 RT randomized trials. Results and conclusions: POLAR score predicted RT benefit and supported omitting adjuvant RT in selected patients, pending validation.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/validation-of-a-breast-cancer-assay-for-radiotherapy-omission-an-individual-participant-data-meta-analysis/369266/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/validation-of-a-breast-cancer-assay-for-radiotherapy-omission-an-individual-participant-data-meta-analysis/369266.png","ImageObject",300,407,{"name":92,"@type":93},"Theodore","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-04","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What is POLAR and what problem does it address?","Question",{"text":112,"@type":113},"POLAR is a 16-gene molecular signature designed to identify low-risk breast cancers where radiotherapy provides no additional reduction in recurrence rates.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was the study conducted?",{"text":117,"@type":113},"The work used an individual participant data meta-analysis of 623 node-negative, estrogen receptor–positive and HER2-negative patients from three RT randomized trials with available primary tumor material.",{"name":119,"@type":110,"acceptedAnswer":120},"What did the results show about patients with high versus low POLAR scores?",{"text":121,"@type":113},"Patients with high POLAR scores benefited substantially from RT, while those with low POLAR scores showed no evidence of RT benefit. POLAR was both prognostic and predictive in selected patients.",{"name":123,"@type":110,"acceptedAnswer":124},"Who may consider omitting adjuvant radiotherapy and what further work is needed?",{"text":125,"@type":113},"The conclusions indicate that patients aged 50 years and older with ER-positive, HER2-negative disease and a low POLAR score could consider omitting adjuvant RT. Further validation in contemporary clinical cohorts is required.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},369266,1790247282,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":143,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":144,"faqs":145,"seo_title":146,"seo_description":67,"update_tm":147,"read_time":148,"preview_page_count":19,"preview_urls":149},7971461740886,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","JNCI: Journal of the National Cancer Institute, 2025, 117(3), 486–495  \n[https://doi.org/10.1093/jnci/djae262](https://doi.org/10.1093/jnci/djae262)  \nAdvance Access Publication Date: October 18, 2024  \nArticle  \nValidation of a breast cancer assay for radiotherapy omission: an individual participant data meta-analysis  \nPer Karlsson , MD, PhD1,2,􀀃 , Anthony Fyles , MD, FRCPC3, S. Laura Chang, PhD4, Bradley Arrick, MD, PhD4, Frederick L. Baehner , MD4, Per Malmstr€om, MD, PhD5,6, Mårtin Fern€o , PhD5, Erik Holmberg , PhD1, Martin Sj€ostr€om , MD, PhD5,7, Fei-Fei Liu , MD, FRCPC3, David A. Cameron , MD8,9, Linda J. Williams , PhD9, John M.S. Bartlett , PhD8, Joanna Dunlop , PhD10, Jacqueline Caldwell , MBA10, Joseph F. Loane, Frcpath11,  \nElizabeth Mallon , Frcpath11, Tammy Piper, MSc8, Ian Kunkler, FRCPE8, Felix Y. Feng , MD7, Corey W. Speers , MD, PhD12, Lori J. Pierce , MD13, John P. Bennett , MPH4, Karen J. Taylor , PhD8  \n1Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, 413 45 Gothenburg, Sweden 2Sahlgrenska Comprehensive Cancer Center, Sahlgrenska University Hospital, Gothenburg, Sweden  \n3Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada 4Exact Sciences Corporation, Madison, WI, United States  \n5Division of Oncology, Department of Clinical Sciences, Lund University, Lund, Sweden  \n6Department of Haematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden 7Department of Radiation Oncology, University of California San Francisco, San Francisco, CA, United States  \n8Cancer Research UK Scotland Centre, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, United Kingdom 9Usher Institute, University of Edinburgh, Edinburgh, United Kingdom  \n10Public Health Scotland, Edinburgh, United Kingdom 11Queen Elizabeth University Hospital, Glasgow, Scotland  \n12Department of Radiation Oncology, Case Comprehensive Cancer Center, OH, United States  \n13Department of Radiation Oncology, Rogel Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI, United States  \n􀀃 Corresponding author: Per Karlsson, MD, PhD, Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Blå Stråket 2, 41345 G€oteborg, Sweden ([per.karlsson@oncology.gu.se](per.karlsson@oncology.gu.se))  \nAbstract  \nBackground: There are currently no molecular tests to identify individual breast cancers where radiotherapy (RT) offers no benefit. Profile for the Omission of Local Adjuvant Radiotherapy (POLAR) is a 16-gene molecular signature developed to identify low-risk cancers where RT will not further reduce recurrence rates.  \nMethods: An individual participant data meta-analysis was performed in 623 patients of node-negative estrogen receptor–positive and HER2-negative early breast cancer enrolled in 3 RT randomized trials for whom primary tumor material was available for analysis. A Cox proportional hazards model on time to locoregional recurrence was used to test the interaction between POLAR score and RT. Results: A total of 429 (69%) patients’ tumors had a high POLAR score, and 194 (31%) had a low score. Patients with high POLAR score had, in the absence of RT, a 10-year cumulative incidence of locoregional recurrence (20%, 95% confidence interval [CI] ¼ 15% to 26%, vs 5%,[CI] 2% to 11%) for those with a low score. Patients with a high POLAR score had a large benefit from RT (hazard ratio [HR] for RT vs no RT ¼ 0.37, 95% CI ¼ 0.23 to 0.60; P \u003C .001). In contrast, there was no evidence of benefit from RT for patients with a low POLAR score (HR ¼ 0.92, 95% CI ¼ 0.42 to 2.02; P ¼ .832). The test for interaction between RT and POLAR was statistically significant (P ¼ .022) . Conclusions: POLAR is not only prognostic for locoregional recurrence but also predictive of benefit from RT in selected patients. Patients aged 50 years and older with estrogen receptor–positive and HER2-negative disease and a","cbCaimpe6o77i9vQ","https://ap.wps.com/l/cbCaimpe6o77i9vQ","pdf",996298,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions","[{\"question\":\"What is POLAR and what problem does it address?\",\"answer\":\"POLAR is a 16-gene molecular signature designed to identify low-risk breast cancers where radiotherapy provides no additional reduction in recurrence rates.\"},{\"question\":\"How was the study conducted?\",\"answer\":\"The work used an individual participant data meta-analysis of 623 node-negative, estrogen receptor–positive and HER2-negative patients from three RT randomized trials with available primary tumor material.\"},{\"question\":\"What did the results show about patients with high versus low POLAR scores?\",\"answer\":\"Patients with high POLAR scores benefited substantially from RT, while those with low POLAR scores showed no evidence of RT benefit. POLAR was both prognostic and predictive in selected patients.\"},{\"question\":\"Who may consider omitting adjuvant radiotherapy and what further work is needed?\",\"answer\":\"The conclusions indicate that patients aged 50 years and older with ER-positive, HER2-negative disease and a low POLAR score could consider omitting adjuvant RT. Further validation in contemporary clinical cohorts is required.\"}]","Validation of a breast cancer assay for radiotherapy omission: an individual participant data meta-analysis | PDF",1790181656,25,[150,154,158,162],{"page_no":8,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/696adbbb0e0bf88d4bb89eeaf89a8053.webp",983,1291,{"page_no":14,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f7a0770fc05c0689181bc4a81d13e0bf.webp",982,1290,{"page_no":81,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2c91701fbf5938c096bb3a00058d0136.webp",981,1289,{"page_no":19,"url":163,"width":164,"height":165},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f235db6d63f6a20bf942bdd343a3b891.webp",980,1287]